Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2010-024359-99 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ABT-639 | Experimental | ABT-639 twice daily for 6 weeks |
|
| pregabalin | Active Comparator | pregabalin starting dose twice daily for week one then titrated up to maintenance dose twice daily for duration of the study |
|
| Placebo | Placebo Comparator | Placebo twice daily for 6 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ABT-639 | Drug | ABT-639 Twice Daily for six weeks. |
| |
| pregabalin |
| Measure | Description | Time Frame |
|---|---|---|
| A mean of 24-hour average pain score measured by an 11-point Numeric Rating Scale (NRS) based on subject's daily diary | Daily questions asked on a hand held diary | Weekly started at Baseline, Week 1, Week 2, Week 4, and Week 6 (End of Study) |
| Measure | Description | Time Frame |
|---|---|---|
| Patient's Global Impression of Change | Paper questionnaire | Week 2, Week 4 and Week 6 (End of Study) |
| Brief Pain Inventory (BPI) (short form) including Severity and Interference | Paper questionnaire |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rachel Duan, MD | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Site Reference ID/Investigator# 51807 | Little Rock | Arkansas | 72204 | United States | ||
| Site Reference ID/Investigator# 51946 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26067585 | Derived | Ziegler D, Duan WR, An G, Thomas JW, Nothaft W. A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain. Pain. 2015 Oct;156(10):2013-2020. doi: 10.1097/j.pain.0000000000000263. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
pregabalin starting dose twice daily for 1 week then titrated to maintenance dose twice daily for the remainder of the study. |
|
|
| Placebo | Drug | Placebo twice daily for 6 weeks. |
|
| At each visit up to Week 6 (end of Study) |
| Neuropathic Pain Symptom Inventory (NPSI) | Paper questionnaire | Baseline, Week 2, Week 4 and Week 6 (end of Study) |
| Anaheim |
| California |
| 92801 |
| United States |
| Site Reference ID/Investigator# 51468 | Long Beach | California | 90806 | United States |
| Site Reference ID/Investigator# 52744 | Walnut Creek | California | 94598 | United States |
| Site Reference ID/Investigator# 51079 | Clearwater | Florida | 33765 | United States |
| Site Reference ID/Investigator# 51076 | Hialeah | Florida | 33012 | United States |
| Site Reference ID/Investigator# 51945 | Hollywood | Florida | 33021 | United States |
| Site Reference ID/Investigator# 51077 | Ocala | Florida | 34471 | United States |
| Site Reference ID/Investigator# 51078 | Orlando | Florida | 32806 | United States |
| Site Reference ID/Investigator# 51804 | Brockton | Massachusetts | 02301 | United States |
| Site Reference ID/Investigator# 51263 | St Louis | Missouri | 63141 | United States |
| Site Reference ID/Investigator# 51268 | St Louis | Missouri | 63141 | United States |
| Site Reference ID/Investigator# 51302 | Omaha | Nebraska | 68131 | United States |
| Site Reference ID/Investigator# 51271 | Flushing | New York | 11365 | United States |
| Site Reference ID/Investigator# 52743 | Portland | Oregon | 97239 | United States |
| Site Reference ID/Investigator# 51806 | Altoona | Pennsylvania | 16602 | United States |
| Site Reference ID/Investigator# 51265 | Tipton | Pennsylvania | 16684 | United States |
| Site Reference ID/Investigator# 51548 | Dallas | Texas | 75231 | United States |
| Site Reference ID/Investigator# 51269 | Renton | Washington | 98055 | United States |
| Site Reference ID/Investigator# 51425 | Hradec Králové | 500 03 | Czechia |
| Site Reference ID/Investigator# 51426 | Mor Ostrava | 702 00 | Czechia |
| Site Reference ID/Investigator# 51424 | Olomouc | 77900 | Czechia |
| Site Reference ID/Investigator# 51428 | Prague | 100 00 | Czechia |
| Site Reference ID/Investigator# 51423 | Prague | 160 00 | Czechia |
| Site Reference ID/Investigator# 51427 | Zlín | 760 01 | Czechia |
| Site Reference ID/Investigator# 51924 | Le Creusot | 71200 | France |
| Site Reference ID/Investigator# 51925 | Vénissieux | 69200 | France |
| Site Reference ID/Investigator# 51503 | Berlin | 10115 | Germany |
| Site Reference ID/Investigator# 51642 | Düsseldorf | 40225 | Germany |
| Site Reference ID/Investigator# 51502 | Mainz | D - 55116 | Germany |
| Site Reference ID/Investigator# 52346 | Münster | 48145 | Germany |
| Site Reference ID/Investigator# 51505 | Guadalajara, Jal. | C.P. 44130 | Mexico |
| Site Reference ID/Investigator# 51504 | Mexico City | C.P. 11650 | Mexico |
| Site Reference ID/Investigator# 51522 | Monterrey, N.L. | C.P. 64000 | Mexico |
| Site Reference ID/Investigator# 51506 | Monterrey, N.L. | C.P. 64460 | Mexico |
| ID | Term |
|---|---|
| D003929 | Diabetic Neuropathies |
| D020422 | Mononeuropathies |
| D010146 | Pain |
| D009437 | Neuralgia |
| ID | Term |
|---|---|
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C000589982 | 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-(hexahydropyrrolo(1,2-a)pyrazin-2(1H)-ylcarbonyl)benzenesulfonamide |
| D000069583 | Pregabalin |
| ID | Term |
|---|---|
| D005680 | gamma-Aminobutyric Acid |
| D000613 | Aminobutyrates |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided